Kinetic studies demonstrated that DuoBody-CD3x5T4 induced efficient T cell–mediated cytotoxicity of 5T4+ MDA-MB-231 breast cancer cells after 48 h, with maximal kill and maximum T-cell activation observed after 72-h incubation (Fig S3D and E). Here, TPBG is linked to breast carcinoma.